LifeMD (LFMD) said Thursday it launched a $299 introductory offer for new self-pay patients prescribed Wegovy, as part of a collaboration with Novo Nordisk (NVO).
The company said the offer includes a discounted $199 price for the medication and $100 for LifeMD's virtual weight loss program. The monthly price rises to $599 starting with the second month and the promotion applies to eligible patients who are prescribed Wegovy by June 30, the company added.
Shares of LifeMD were down more than 4% in recent Thursday premarket activity, while Novo Nordisk stock fell 2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.